Navigation Links
Moffitt Cancer Center begins Phase I clinical trial of new immunotherapy
Date:4/9/2014

Moffitt Cancer Center has initiated a phase I clinical trial for a new immunotherapy drug, ID-G305, made by Immune Design. Immunotherapy is a treatment option that uses a person's own immune system to fight cancer. It has several advantages over standard cancer therapies, including fewer side effects and an overall better tolerability. It tends to be most effective in patients who have smaller, localized tumors that have not spread to distant sites.

"This clinical trial is to assess ID-G305 and its ability to activate the immune system in patients with advanced stage melanoma, sarcoma, lung, ovarian, or breast cancer," said Amit Mahipal, M.D., M.P.H., medical director of Moffitt's Clinical Research Unit. "Our first patient in this trial is a metastatic sarcoma patient who has undergone two previous surgeries and one chemotherapy regimen."

ID-G305 is a cancer vaccine that is made up of two parts, a protein called NY-ESO-1 that is found in many different types of cancer, and an agent called GLAASTM developed by Immune Design. GLAASTM activates a type of cell called a dendritic cell that normally searches for pathogens in the body and helps the immune system fight against the infection. Following vaccination, the GLAASTM-activated dendritic cells recognize NY-ESO-1 as a foreign protein and cause the body to produce an immune response. Since NY-ESO-1 is found on tumors, the immune system begins targeting the cancer cells.

"Only 10 to 15 percent of all tumors have NY-ESO-1 protein expression. Therefore, patients for this trial need to be to be screened for NY-ESO-1. The vaccine will likely not work for patients with tumors that do not have detectable levels of the protein," said Mahipal.

Each component of ID-G305 has been used previously as a single-agent in clinical trials and was well tolerated by patients. This trial will determine the ideal concentration of each agent to use in combination. Common side effects expected include pain, redness, and inflammation at the site of injection.

This is an exciting time for the development of new immunotherapies to fight cancer. Several immunotherapy agents have recently been approved by the Food and Drug Administration, including interleukin-2 for melanoma and renal cell carcinoma, Provenge for prostate cancer and ipilimumab for melanoma.

"New immune therapies are emerging," explained Mahipal. "If we can have immune therapy actually work it would be great for the patient and reduce side effects associated with traditional chemotherapies."


'/>"/>

Contact: Kim Polacek
kim.polacek@moffitt.org
813-745-7408
H. Lee Moffitt Cancer Center & Research Institute
Source:Eurekalert

Related medicine news :

1. Moffitt instrumental in FDA approval of revolutionary 2-drug combo to treat advanced melanoma
2. Moffitt Cancer Center launches prostate cancer study focused on black men
3. Single injection may revolutionize melanoma treatment, Moffitt study shows
4. Moffitt researchers identify gene variations that may help predict cancer treatment response
5. Moffitt Cancer Center expert standardizing guidelines for penile cancer treatment
6. Protein complex linked to cancer growth may also help fight tumors, Moffitt researchers say
7. Single men, smokers at higher risk for oral human papillomavirus infection, Moffitt study shows
8. How to boost Hispanics participation in clinical trials? Relate to them, Moffitt study shows
9. New screening approach identifies small proteins unique to melanoma cells, Moffitt researcher says
10. Virus combination effective against deadly brain tumor, Moffitt Cancer Center study shows
11. Moffitt Cancer Center researchers identify genetic variants predicting aggressive prostate cancers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/17/2017)... Wilmington, Delaware (PRWEB) , ... August 17, 2017 , ... ... bedside, well actually, stretcher side nurse, she took with her a dream to make ... science of healthcare. Specifically, ensuring communication skills were integrated into healthcare provider education. ...
(Date:8/17/2017)... (PRWEB) , ... August 17, 2017 , ... Georgia ... welcome Dr. Kristi Hebert to its newest location in East Cobb ... to have Dr. Hebert come aboard,” said Dr. Mark A. Haber, Georgia Urology’s managing ...
(Date:8/17/2017)... ... August 17, 2017 , ... Elemental LED, a leading U.S. based ... Diode LED products were honored with Architectural SSL Product Innovation Awards (PIA) ... manufacturing and wholesale division, Diode LED, provides a wide variety of superior quality linear, ...
(Date:8/17/2017)... ... August 17, 2017 , ... The Skoll Foundation, ... bold systems change models helping to achieve progress towards the Sustainable Development Goals ... “We the Future: Accelerating Sustainable Development Solutions” at TED Theater in New York, ...
(Date:8/17/2017)... ... August 17, 2017 , ... Florida ... August 16, to community partners. The newly renovated ER was designed with patients ... minor emergencies, eight semi-private rooms to deliver patient results, improve efficiencies and reduce ...
Breaking Medicine News(10 mins):
(Date:8/8/2017)... 8, 2017  BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage ... its financial results for the second quarter ended June ... second quarter 2017 and to date: ... programs for the Company,s lead project, BL-8040: ... with BL-8040 as novel stem cell mobilization treatment for ...
(Date:8/7/2017)... (NYSE: DPLO), the nation,s largest independent specialty pharmacy, announced financial ... unless otherwise noted, are to the quarter ended June 30, ... 2017 Highlights include: Revenue of $1,126 ... Total prescriptions dispensed of 220,000, compared to 241,000 ... Gross profit per prescription dispensed of $371, ...
(Date:8/2/2017)... , Aug. 2, 2017 ... Who,s Who as a Pinnacle Lifetime Professional in ... Key Account Manager at Turing Pharmaceuticals, AG. Her ... troubleshooting and relationship building.                ... more than 25 years of experience as a ...
Breaking Medicine Technology: